Dyspepsia

Current Opinion in Gastroenterology

Volumn 28, Issue 6, 2012, Pages 602-607

  Moayyedi, Paul ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

diet; dyspepsia; epigastric pain; microbiome; nonulcer dyspepsia

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTERIOR CINGULATE; ASIA; BACTERIAL CLEARANCE; BAROSTAT; BARRETT ESOPHAGUS; CEREBELLUM; CINGULATE GYRUS; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DYSPEPSIA; ERADICATION THERAPY; ESOPHAGITIS; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; INSULA; MIDDLE CINGULATE CORTEX; PEPTIC ULCER; PREVOTELLA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); THALAMUS; UPPER GASTROINTESTINAL TRACT;

ANTI-BACTERIAL AGENTS; DIET THERAPY; DYSPEPSIA; ENDOSCOPY, DIGESTIVE SYSTEM; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRACT; HELICOBACTER INFECTIONS; HUMANS; METAGENOME; PROTON PUMP INHIBITORS;

EID: 84868348386     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328358ad9b     Document Type: Review

References (112)

1. Marwaha A, Ford AC, Lim A, Moayyedi P. The worldwide prevalence of dyspepsia: systematic review and meta-analysis. Gastroenterology 2009; 136 (Suppl 1):A149.
2. Ford AC, Forman D, Bailey AG, et al. Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol 2012; 107:912-921.
3. van Zanten SV, Wahlqvist P, Talley NJ, et al. Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole - results from the STARS II study. Aliment Pharmacol Therap 2011; 34:714-723.
4. Shanahan F. Darwinian dyspepsia: an extraordinary scientist, an ordinary illness, great dignity. Am J Gastroenterol 2012; 107:161-164.
5. Oustamanolakis P, Tack J. Dyspepsia: organic versus functional. J Clin Gastroenterol 2012; 46:175-190.
6. Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic finding in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8:830-837.
7. Li Z, Zou D, Ma X, et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 2010; 105:2570-2577.
8. Zagari RM, Law GR, Fuccio L, et al. Dyspeptic symptoms and endoscopic findings in the community: the Loiano-Monghidoro study. Am J Gastroenterol 2010; 105:565-571.
9. Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99:1833-1855.
10. Moayyedi P, Talley NJ. Gastro-esophageal reflux disease. Lancet 2006; 367:2086-2100.
11. Lacy BE, Talley NJ, Locke GR III, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012; 36:3-15.
12. Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129:1756-1780.
13. Tack J, Masaoka T, Janssen P. Functional dyspepsia. Curr Opin Gastroenterol 2011; 27:549-557.
14. Van Oudenhove L, Vandenberghe J, Dupont P, et al. Abnormal regional brain activity during rest and (anticipated) gastric distension in functional dyspepsia and the role of anxiety: a H(2)(15)O-PET study. Am J Gastroenterol 2010; 105:913-924.
15. Oshima T, Okugawa T, Tomita T, et al. Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjects. Aliment Pharmacol Therap 2012; 35:175-182.
16. Ishii M, Kusunoki H, Manabe N, et al. Evaluation of duodenal hypersensitivity induced by duodenal acidification using transnasal endoscopy. J Gastroenterol Hepatol 2010; 25:913-918.
17. Mirbagheri SA, Khajavirad N, Rakhshani N, et al. Impact of Helicobacter pylori infection and microscopic duodenal histopathological changes on clinical symptoms of patients with functional dyspepsia. Dig Dis Sci 2012; 57:967-972.
18. Zeng F, Qin W, Liang F, et al. Abnormal resting brain activity in patients with functional dyspepsia is related to symptom severity. Gastroenterology 2011; 141:499-506.
19. Bollegala NP, Khanna R, Moayyedi P, Leontiadis GI. Prokinetics for functional dyspepsia. Cochrane Database Syst Rev (in press).
20. Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: what are we treating? Arch Int Med 2011; 171:1936-1937.
21. Moayyedi P, Soo S, Deeks J, et al. Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for nonulcer dyspepsia. Aliment Pharmacol Therap 2003; 17:1207-1214.
22. Moayyedi P, Delaney B, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127:1329-1337.
23. Wu JC, Cheong PK, Chan Y, et al. A randomized, double-blind, placebocontrolled trial of low dose imipramine for treatment of refractory functional dyspepsia. Gastroenterology 2011; 140 (supplement 1):S50.
24. Abraham NS, Moayyedi P, Daniels B, Veldhuyzen Van Zanten SJO. Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (nonulcer) dyspepsia. Aliment Pharmacol Therap 2004; 19:631-641.
25. Xiao YL, Peng S, Tao J, et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol 2010; 105:2626-2631.
26. Savarino E, Zentilin P, Dulbecco P, et al. The role of acid in functional dyspepsia. Am J Gastroenterol 2011; 106:1168.
27. Fletcher J, Derakhshan MH, Jones GR, et al. BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy. Gut 2011; 60:442-448.
28. Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter 2011; 16:343-345.
29. De Francesco V, Giorgio F, Ierardi E, et al. Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarithromycin Resistance Observational (MICRO) study. J Gastrointest Liver Dis 2011; 20:235-239.
30. Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.AmJ Gastroenterol 2011; 106:1970-1975.
31. Watson JB, Moss SF. Will H. Pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. Am J Gastroenterol 2011; 106:1976-1977.
32. Talley NJ, Walker MM, Aro P, et al. Nonulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007; 5:1175-1183.
33. Veerappan GR, Moawad FJ, Duncan TJ, et al. Non-ulcer dyspepsia not associated with gastric or duodenal eosinophilia. Gastroenterology 2009; 136 (supplement 1):A58.
34. Walker MM, Salehian SS, Murray CE, et al. Implications of eosinophilia in the normal duodenal biopsy: an association with allergy and functional dyspepsia. Aliment Pharmacol Ther 2010; 31:1229-1236.
35. Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophils and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol 2010; 105:1835-1842.
36. Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011; 106:1089-1098.
37. Ford AC, Ching E, Moayyedi P. Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. Aliment Pharmacol Therap 2009; 30: 28-36.
38. Ozaslan E, Akkorlu S, Eskioglu E, Kayhan B. Prevalence of silent celiac disease in patients with dyspepsia. Dig Dis Sci 2007; 52:692-697.
39. Di Sabatino A, Corazza GR. Nonceliac gluten sensitivity: sense or sensibility? Ann Intern Med 2012; 156:309-311.
40. Biesiekierski JR, Newnham ED, Irving PM, et al.Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106:508-514.
41. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and metaanalysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010; 8:401-409.
42. Saito YA, Locke GR 3rd, Weaver AL, et al. Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol 2005; 100:2743-2748.
43. van Boxel OS, ter Linde JJ, Siersema PD, Smout AJ. Role of chemical stimulation of the duodenum in dyspeptic symptom generation. Am J Gastroenterol 2010; 105:803-811.
44. Gibson PR, Shepherd SJ. Food choice as a key management strategy for functional gastrointestinal symptoms. Am J Gastroenterol 2012; 107:657-666.
45. Hu Y, He LH, Xiao D, et al. Bacterial flora concurrent with Helicobacter pylori in the stomach of patients with upper gastrointestinal diseases. World J Gastroenterol 2012; 18:1257-1261.
46. Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. PNAS 2006; 103:732-737.
47. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012; 13:260-270.
48. Ishii M, Manabe N, Kusunoki H, et al. Real-time evaluation of dyspeptic symptoms and gastric motility induced by duodenal acidification using noninvasive transnasal endoscopy. J Gastroenterol 2008; 43:935-941.
49. Zanini B, Ricci C, Bandera F, et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol 2012; 107:891-899.
50. Kindt S, Van Oudenhove L, Mispelon L, et al. Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: a 5-year follow-up study. Am J Gastroenterol 2011; 106:340-348.
51. Ford AC, Thabane M, Collins SM, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: cohort study. Gastroenterology 2010; 138:373-378.
52. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2012. doi:10.1136/gutjnl-2012- 302167.
53. Walter J, Ley R. The human gut microbiome: ecology and recent evolutionary changes. Annu Rev Microbiol 2011; 65:411-429.
54. Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011; 41:380-386.
55. Ratuaplli SK, Ellington TG, O'Neil M-T, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol 2012; 107:730-735.
56. Brook RA, Kleinman NL, Choung RS, et al. Excess comorbidity prevalence and cost associated with functional dyspepsia in an employed population. Dig Dis Sci 2012; 57:109-118.
57. Marwaha A, Ford AC, Lim A, Moayyedi P. The worldwide prevalence of dyspepsia: systematic review and meta-analysis. Gastroenterology 2009; 136 (Suppl 1):A149.
58. Ford AC, Forman D, Bailey AG, et al. Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol 2012; 107:912-921.
59. van Zanten SV, Wahlqvist P, Talley NJ, et al. Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole - results from the STARS II study. Aliment Pharmacol Therap 2011; 34:714-723.
60. Shanahan F. Darwinian dyspepsia: an extraordinary scientist, an ordinary illness, great dignity. Am J Gastroenterol 2012; 107:161-164.
61. Oustamanolakis P, Tack J. Dyspepsia: organic versus functional. J Clin Gastroenterol 2012; 46:175-190.
62. Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic finding in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8:830-837.
63. Li Z, Zou D, Ma X, et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 2010; 105:2570-2577.
64. Zagari RM, Law GR, Fuccio L, et al. Dyspeptic symptoms and endoscopic findings in the community: the Loiano-Monghidoro study. Am J Gastroenterol 2010; 105:565-571.
65. Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99:1833-1855.
66. Moayyedi P, Talley NJ. Gastro-esophageal reflux disease. Lancet 2006; 367:2086-2100.
67. Lacy BE, Talley NJ, Locke GR III, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012; 36:3-15.
68. Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129:1756-1780.
69. Tack J, Masaoka T, Janssen P. Functional dyspepsia. Curr Opin Gastroenterol 2011; 27:549-557.
70. Van Oudenhove L, Vandenberghe J, Dupont P, et al. Abnormal regional brain activity during rest and (anticipated) gastric distension in functional dyspepsia and the role of anxiety: a H(2)(15)O-PET study. Am J Gastroenterol 2010; 105:913-924.
71. Oshima T, Okugawa T, Tomita T, et al. Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjects. Aliment Pharmacol Therap 2012; 35:175-182.
72. Ishii M, Kusunoki H, Manabe N, et al. Evaluation of duodenal hypersensitivity induced by duodenal acidification using transnasal endoscopy. J Gastroenterol Hepatol 2010; 25:913-918.
73. Mirbagheri SA, Khajavirad N, Rakhshani N, et al. Impact of Helicobacter pylori infection and microscopic duodenal histopathological changes on clinical symptoms of patients with functional dyspepsia. Dig Dis Sci 2012; 57:967-972.
74. Zeng F, Qin W, Liang F, et al. Abnormal resting brain activity in patients with functional dyspepsia is related to symptom severity. Gastroenterology 2011; 141:499-506.
75. Bollegala NP, Khanna R, Moayyedi P, Leontiadis GI. Prokinetics for functional dyspepsia. Cochrane Database Syst Rev (in press).
76. Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: what are we treating? Arch Int Med 2011; 171:1936-1937.
77. Moayyedi P, Soo S, Deeks J, et al. Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for nonulcer dyspepsia. Aliment Pharmacol Therap 2003; 17:1207-1214.
78. Moayyedi P, Delaney B, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127:1329-1337.
79. Wu JC, Cheong PK, Chan Y, et al. A randomized, double-blind, placebocontrolled trial of low dose imipramine for treatment of refractory functional dyspepsia. Gastroenterology 2011; 140 (supplement 1):S50.
80. Abraham NS, Moayyedi P, Daniels B, Veldhuyzen Van Zanten SJO. Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (nonulcer) dyspepsia. Aliment Pharmacol Therap 2004; 19:631-641.
81. Xiao YL, Peng S, Tao J, et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol 2010; 105:2626-2631.
82. Savarino E, Zentilin P, Dulbecco P, et al. The role of acid in functional dyspepsia. Am J Gastroenterol 2011; 106:1168.
83. Fletcher J, Derakhshan MH, Jones GR, et al. BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy. Gut 2011; 60:442-448.
84. Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter 2011; 16:343-345.
85. De Francesco V, Giorgio F, Ierardi E, et al. Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarithromycin Resistance Observational (MICRO) study. J Gastrointest Liver Dis 2011; 20:235-239.
86. Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.AmJ Gastroenterol 2011; 106:1970-1975.
87. Watson JB, Moss SF. Will H. Pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. Am J Gastroenterol 2011; 106:1976-1977.
88. Talley NJ, Walker MM, Aro P, et al. Nonulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007; 5:1175-1183.
89. Veerappan GR, Moawad FJ, Duncan TJ, et al. Non-ulcer dyspepsia not associated with gastric or duodenal eosinophilia. Gastroenterology 2009; 136 (supplement 1):A58.
90. Walker MM, Salehian SS, Murray CE, et al. Implications of eosinophilia in the normal duodenal biopsy: an association with allergy and functional dyspepsia. Aliment Pharmacol Ther 2010; 31:1229-1236.
91. Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophils and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol 2010; 105:1835-1842.
92. Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011; 106:1089-1098.
93. Ford AC, Ching E, Moayyedi P. Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. Aliment Pharmacol Therap 2009; 30: 28-36.
94. Ozaslan E, Akkorlu S, Eskioglu E, Kayhan B. Prevalence of silent celiac disease in patients with dyspepsia. Dig Dis Sci 2007; 52:692-697.
95. Di Sabatino A, Corazza GR. Nonceliac gluten sensitivity: sense or sensibility? Ann Intern Med 2012; 156:309-311.
96. Biesiekierski JR, Newnham ED, Irving PM, et al.Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106:508-514.
97. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and metaanalysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010; 8:401-409.
98. Saito YA, Locke GR 3rd, Weaver AL, et al. Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol 2005; 100:2743-2748.
99. van Boxel OS, ter Linde JJ, Siersema PD, Smout AJ. Role of chemical stimulation of the duodenum in dyspeptic symptom generation. Am J Gastroenterol 2010; 105:803-811.
100. Gibson PR, Shepherd SJ. Food choice as a key management strategy for functional gastrointestinal symptoms. Am J Gastroenterol 2012; 107:657-666.
101. Hu Y, He LH, Xiao D, et al. Bacterial flora concurrent with Helicobacter pylori in the stomach of patients with upper gastrointestinal diseases. World J Gastroenterol 2012; 18:1257-1261.
102. Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. PNAS 2006; 103:732-737.
103. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012; 13:260-270.
104. Ishii M, Manabe N, Kusunoki H, et al. Real-time evaluation of dyspeptic symptoms and gastric motility induced by duodenal acidification using noninvasive transnasal endoscopy. J Gastroenterol 2008; 43:935-941.
105. Zanini B, Ricci C, Bandera F, et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol 2012; 107:891-899.
106. Kindt S, Van Oudenhove L, Mispelon L, et al. Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: a 5-year follow-up study. Am J Gastroenterol 2011; 106:340-348.
107. Ford AC, Thabane M, Collins SM, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: cohort study. Gastroenterology 2010; 138:373-378.
108. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2012. doi:10.1136/gutjnl-2012- 302167.
109. Walter J, Ley R. The human gut microbiome: ecology and recent evolutionary changes. Annu Rev Microbiol 2011; 65:411-429.
110. Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011; 41:380-386.
111. Ratuaplli SK, Ellington TG, O'Neil M-T, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol 2012; 107:730-735.
112. Brook RA, Kleinman NL, Choung RS, et al. Excess comorbidity prevalence and cost associated with functional dyspepsia in an employed population. Dig Dis Sci 2012; 57:109-118.